Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients |
Haroon, Saroona
(Department of Pathology and Microbiology, Aga Khan University Hospital)
Hashmi, Atif Ali (Department of Histopathology, Liaquat National Hospital and Medical College) Khurshid, Amna (Department of Histopathology, Liaquat National Hospital and Medical College) Kanpurwala, Muhammad Adnan (Department of Physiology, Muhammad Bin Qasim Medical and Dental College) Mujtuba, Shafaq (Department of Histopathology, Liaquat National Hospital and Medical College) Malik, Babar (Department of Medical Oncology, Sindh Institute of Urology and Transplantation) Faridi, Naveen (Department of Histopathology, Liaquat National Hospital and Medical College) |
1 | Aleskandarany MA, Rakha EA, Macmillan RD, et al (2010). MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat, 127, 591-9. |
2 | Awadelkarim KD, Costantini RM, Osman I, Barberis MC (2012). Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study. ISRN Pathology. |
3 | Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE (2002). Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat, 71, 161-70. DOI ScienceOn |
4 | Bonnefoi H, Underhill C, Iggo R, Cameron D (2009). Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? Eur J Cancer, 45, 1733-43. DOI ScienceOn |
5 | Bottini A (2005). Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a singleinstitution phase III trial. Endocr Relat Cancer, 12, 383-92. DOI ScienceOn |
6 | Collins LC, Botero ML, Schnitt SJ (2005). Bimodal frequency distribution of Estrogen Receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol, 123, 16-20. DOI ScienceOn |
7 | Colozza M, Azambuja E, Cardoso F et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer :where are we now? Ann Oncol, 16, 1723-27. DOI ScienceOn |
8 | Cuzick J, Dowsett M, Wale C, et al (2009). Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and the comparison with the GHI recurrence score-results from TransATAC. Cancer Res, 69, 503. |
9 | Dai H, vant Veer L, Lamb J, et al (2005). A cell proliferation signature is a marker ofextremely poor outcome in a subpopulation of breast cancer patients. Cancer Res, 65, 4059-66. DOI ScienceOn |
10 | Desmedt C, Sotiriou C (2006). Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle, 5, 2198-202. DOI |
11 | Dowsett M (2006). Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res, 12, 1024-30. DOI ScienceOn |
12 | Dowsett M, Procter M, McCaskill-Stevens W, et al (2009). Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol, 27, 2962-69. DOI ScienceOn |
13 | Ellis LM, Fidler IJ (1996). Angiogenesis and metastasis. Eur J Cancer, 32, 2451-60. DOI ScienceOn |
14 | Gerdes J, Lemke H, Baisch H, et al (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133, 1710-5. |
15 | Eppenberger U, Kueng W, Schlaeppi JM, et al (1998). Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol, 16, 3129-36. |
16 | Fasching PA, Heusinger K, Haeberle L, et al (2011). Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 11, 486. DOI |
17 | Ferguson NL, Bell J, Heidel R, et al (2013). Prognostic value of breast cancer subtypes, ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in caucasian women. Breast J, 19, 22-30. DOI ScienceOn |
18 | Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20. DOI |
19 | Gerdes J, Li L, Schlueter C, et al (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 138, 867-73. |
20 | Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29. DOI ScienceOn |
21 | Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22,1736-47. DOI ScienceOn |
22 | Keshgegian AA, Cnaan A (1995). Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol. 104, 42-9. |
23 | Haerslev T, Jacobsen GK, Zedeler K (1996). Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry withhistopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat, 37, 101-13. DOI |
24 | Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70. DOI ScienceOn |
25 | Harris L, Fritsche H, Mennel R, et al (2007). American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312. DOI ScienceOn |
26 | Learn PA, Yeh IT, McNutt M, et al (2005). HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer, 103, 2252-60. DOI ScienceOn |
27 | Luporsi E, André F, Spyratos F, et al (2012). Ki-67: level of evidence and methodological considerations forits role inthe clinical management of breastcancer: analytical and critical review. Breast Cancer Res Treat, 132, 895-915. DOI |
28 | Matsubara N, Mukai H, Fujii S, Wada N (2013). Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat, 137, 203-12. DOI |
29 | Molino A, Micciolo R, Turazza M, et al (1997). Ki-67 immunostaining in 322primary breast cancers: associations with clinical and pathological variablesand prognosis. Int J Cancer, 74, 433-7. DOI |
30 | Railo M, Luldin J, Haglund C, von Smitten K, Nordling S (2007). Ki-67, ER receptors, ploidy and S phase as longterm prognostic factors in T1 node-negative breast cancer. Tumour Biol, 28, 45-51. DOI ScienceOn |
31 | Sharifi SN, Sadeghian F, Homaei SF,Haghighi F (2006). Immunohistochemical study of cell proliferation marker (ki-67), estrogen, and progesterone receptors expression in breast carcinoma. J Birjand Uni Med Sci, 3, 38-44. |
32 | Reyal F, Hajage D, Savignoni A, et al (2013). Long-term prognostic performance of Ki67 rate in early stage, pT1- pT2, pN0, invasive breast carcinoma. PLoS One, 8, 55901. DOI |
33 | Royston P, Altman DG, Sauerbrei W (2006). Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med, 25, 127-41. DOI ScienceOn |
34 | Sahin AA, Ro J, Ro JY, et al (1991). Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer, 68, 549-7. DOI ScienceOn |
35 | Smith IE, Dowsett M, Ebbs SR, et al (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23, 5108-16. DOI ScienceOn |
36 | Strand C, Bak M, Borgquist S, et al (2013). The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. Springerplus, 2, 111 DOI |
37 | Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast cancer, its association with grading systems, clinical parameters and other prognostic factors e a surrogate marker? Cancer, 97, 1321-31. DOI ScienceOn |
38 | Van Diest PJ, van der Wall E, Baak JP (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 57, 675-81. DOI ScienceOn |
39 | Whitfield ML, George LK, Grant GD et al (2006). Common markers of proliferation. Nat Rev Cancer, 6, 99-106 DOI ScienceOn |
40 | Viale G, Regan MM, Mastropasqua MG, et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12. DOI ScienceOn |
41 | Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45. |